Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Veloxis Pharmaceuticals A/S Issues FY 2013 Earnings Guidance in Line with Analysts' Estimates


Wednesday, 6 Mar 2013 02:51am EST 

Veloxis Pharmaceuticals A/S announced that it expects to report fiscal year 2013 operating loss in a range of between DKK 170 million and DKK 200 million. The fiscal year 2013 net loss is likewise expected to be in the range of between DKK 170 million and DKK 200 million. According to I/B/E/S estimates, analysts on average are expecting the Company to report fiscal year 2013 operating profit (EBIT) of negative DKK 179 million and fiscal year 2013 net profit of negative DKK 186 million.